皮质类固醇、血浆置换、阿加曲班、利妥昔单抗和西罗莫司对一名有肝素诱导的血小板减少症病史的灾难性抗磷脂综合征患者具有临床益处。
Corticosteroids, Plasmapheresis, Argatroban, Rituximab, and Sirolimus Provided Clinical Benefit for Catastrophic Antiphospholipid Syndrome in a Patient with a History of Heparin-Induced Thrombocytopenia.
作者信息
Hasan Haytham, Surjancev Ivana, Arnason Jon A, Garg Shivani, Rose William Nicholas
机构信息
Department of Pathology, University of Wisconsin Hospital, 600 Highland Ave, Madison, WI 53792, USA.
Department of Medicine, University of Wisconsin Hospital, 600 Highland Ave, Madison, WI 53792, USA.
出版信息
Case Rep Rheumatol. 2023 Feb 9;2023:3226278. doi: 10.1155/2023/3226278. eCollection 2023.
Abstract
We report a patient with catastrophic antiphospholipid syndrome who had significant improvement after corticosteroids, plasmapheresis, argatroban, rituximab, and sirolimus. Argatroban was used instead of heparin due to a history of heparin-induced thrombocytopenia.
摘要
我们报告了一名患有灾难性抗磷脂综合征的患者，其在接受皮质类固醇、血浆置换、阿加曲班、利妥昔单抗和西罗莫司治疗后有显著改善。由于有肝素诱导的血小板减少病史，故使用阿加曲班替代肝素。
相似文献
1
Corticosteroids, Plasmapheresis, Argatroban, Rituximab, and Sirolimus Provided Clinical Benefit for Catastrophic Antiphospholipid Syndrome in a Patient with a History of Heparin-Induced Thrombocytopenia.
Case Rep Rheumatol. 2023 Feb 9;2023:3226278. doi: 10.1155/2023/3226278. eCollection 2023.
2
Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia.
Am J Hematol. 2008 Mar;83(3):245-6. doi: 10.1002/ajh.21072.
3
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab.
Autoimmun Rev. 2013 Sep;12(11):1085-90. doi: 10.1016/j.autrev.2013.05.004. Epub 2013 Jun 15.
4
Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment.
Lupus. 2018 Aug;27(9):1552-1558. doi: 10.1177/0961203318768890. Epub 2018 Apr 10.
5
Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban.
Lupus. 2020 Jun;29(7):787-790. doi: 10.1177/0961203320914363. Epub 2020 Mar 29.
6
A case of catastrophic antiphospholipid syndrome: first report with advanced cardiac imaging using MRI.
Lupus. 2015 Oct;24(12):1338-41. doi: 10.1177/0961203315587960. Epub 2015 May 26.
7
Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Ann Pharmacother. 2006 May;40(5):972-6. doi: 10.1345/aph.1G319. Epub 2006 Mar 28.
8
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Circulation. 2001 Apr 10;103(14):1838-43. doi: 10.1161/01.cir.103.14.1838.
9
The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment.
Cardiol Rev. 2006 Jan-Feb;14(1):7-13. doi: 10.1097/01.crd.0000164011.17381.6f.
10
Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.
Thromb Res. 2005;116(2):121-6. doi: 10.1016/j.thromres.2004.11.006. Epub 2004 Dec 8.
引用本文的文献
1
Unresolved issues in the diagnosis and management of thrombotic antiphospholipid syndrome.
Res Pract Thromb Haemost. 2025 Mar 7;9(2):102724. doi: 10.1016/j.rpth.2025.102724. eCollection 2025 Feb.
2
Catastrophic Antiphospholipid Syndrome.
Int J Mol Sci. 2024 Jan 4;25(1):668. doi: 10.3390/ijms25010668.
本文引用的文献
1
Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature.
Medicina (Kaunas). 2021 Aug 31;57(9):912. doi: 10.3390/medicina57090912.
2
Antiphospholipid syndrome: the need for new international classification criteria.
Expert Rev Clin Immunol. 2021 Apr;17(4):385-394. doi: 10.1080/1744666X.2021.1900733. Epub 2021 Mar 17.
3
Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review.
Biomedicines. 2021 Feb 8;9(2):166. doi: 10.3390/biomedicines9020166.
4
Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.
Arthritis Care Res (Hoboken). 2021 Oct;73(10):1490-1501. doi: 10.1002/acr.24520. Epub 2021 Sep 2.
5
An update on the management of antiphospholipid syndrome.
Ther Adv Musculoskelet Dis. 2020 Apr 27;12:1759720X20910855. doi: 10.1177/1759720X20910855. eCollection 2020.
6
mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report.
Am J Kidney Dis. 2020 Aug;76(2):288-291. doi: 10.1053/j.ajkd.2019.08.032. Epub 2019 Dec 4.
7
Is there a role for immunosuppression in antiphospholipid syndrome?
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):426-432. doi: 10.1182/hematology.2019000073.
8
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.
Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. eCollection 2019.
9
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.
J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705.
10
B Cells as a Therapeutic Target in Paediatric Rheumatic Disease.
Front Immunol. 2019 Feb 14;10:214. doi: 10.3389/fimmu.2019.00214. eCollection 2019.
Zotero 插件